DaVita (NYSE:DVA) Posts Earnings Results, Misses Estimates By $0.17 EPS

DaVita (NYSE:DVA) posted its quarterly earnings data on Tuesday. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17), Briefing.com reports. The firm had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the business posted $2.85 EPS. DaVita updated its FY24 guidance to $9.25-$10.05 EPS and its FY 2024 guidance to 9.250-10.050 EPS.

DaVita Stock Down 10.8 %

DVA stock opened at $141.16 on Thursday. The stock has a fifty day moving average of $158.21 and a 200-day moving average of $146.02. DaVita has a fifty-two week low of $76.17 and a fifty-two week high of $168.50. The company has a market capitalization of $11.84 billion, a price-to-earnings ratio of 15.03, a PEG ratio of 0.90 and a beta of 0.87. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16.

Analyst Ratings Changes

DVA has been the topic of a number of recent analyst reports. Truist Financial lifted their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Bank of America lifted their target price on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. UBS Group increased their price target on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, TD Cowen lifted their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, DaVita currently has an average rating of “Hold” and an average target price of $159.00.

Insider Activity at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the transaction, the insider now owns 83,011 shares in the company, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the transaction, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 173,482 shares of company stock worth $27,387,069. Company insiders own 2.00% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.